Endothelin receptor antagonist
Combined use of ursodeoxycholic acid and bosentan prevents liver toxicity caused by endothelin receptor antagonist bosentan monotherapy: two case reports
... Introduction: Pulmonary arterial hypertension is a fatal disease characterized by progressive remodeling of the pulmonary arteries and an increase in pulmonary vascular resistance. Up to 50% of patients with systemic ...
5
Endothelin receptor antagonist and airway dysfunction in pulmonary arterial hypertension
... wall thickening, and lymphocyte infiltrates, thereby sup- porting earlier observations after necropsy [3,17]. On the other hand in 22 patients with IPAH, a single inha- lation of beta-2-agonsists resulted in acute ...
7
Original Article Effect of mixed endothelin receptor antagonist bosentan on brain damage after experimental cardiac arrest
... dual endothelin receptor (ETR) antagonist-bosentan on post ischemic ultrastructural abnormalities and endothelin binding sites in the brain after 10 min cardiac arrest in ...
17
Potent anti inflammatory and antinociceptive activity of the endothelin receptor antagonist bosentan in monoarthritic mice
... AIA in mice. Mice received daily oral administrations for 21 days beginning 2 hours before induction of AIA. Knee joint swelling and pain-related behavior were assessed repeatedly during the course of AIA (Figure 1a). On ...
9
Effects of endothelin receptor antagonist on cyclosporine induced vasoconstriction in isolated rat renal arterioles
... ETA receptor antagonist was verified in both the AA and EA, where it was found that the cyclic peptide cyclo D-Asp-L-Pro-D-Val- L-Leu-D-Trp totally inhibited the vasoconstriction observed with ET ...ETA ...
7
VIP and endothelin receptor antagonist: An effective combination against experimental pulmonary arterial hypertension
... an endothelin (ET) receptor antagonist bosentan enhance its efficacy? Methods: Within 3 weeks of a single injection of monocrotaline (MCT, ...down-regulates endothelin receptor ...
7
<p>Single- and multiple-dose tolerability, safety, pharmacokinetics, and pharmacodynamics of the dual endothelin receptor antagonist aprocitentan in healthy adult and elderly subjects</p>
... Subjects and methods: In this study, the single- and multiple-dose tolerability, safety, phar- macokinetics (PK), and pharmacodynamics of up to 600 mg (single doses) and 100 mg once a day (qd; multiple doses) of ...
16
New horizons in pulmonary arterial hypertension therapies
... Data from the large, multicentre, double-blind phase III SERAPHIN (Study with an Endothelin Receptor Antagonist in Pulmonary Arterial Hypertension to Improve Clinical Outcome) trial have recently ...
12
Therapeutic targets in systemic sclerosis
... dual endothelin receptor antagonist bosentan, which has been shown to manage two vascular complications of SSc effectively: pulmonary arterial hypertension and digital ...
5
Role of endothelin receptor A and NADPH oxidase in vascular abnormalities
... upregulated endothelin receptor A (ETA) in the vasculature in association with a decline in nitric oxide ...beds. Endothelin receptor antagonist CPU0213 and ingredients from plant ...
8
The effect of Bosentan on healing of colonic anastomosis
... an endothelin- receptor antagonist, can eliminate vasoconstruction, increase blood flow in the splanchnic area and anastomotic region and therefore possibly facilitate wound healing and prevent ...
5
New perspectives in long-term outcomes in clinical trials of pulmonary arterial hypertension
... an Endothelin Receptor Antagonist in Pulmonary Arterial Hypertension to Improve Clinical Outcomes) trial of the novel dual endothelin receptor antagonist macitentan has recently ...
8
<p>Management of digital ulcers in systemic sclerosis</p>
... Effect of the endothelin type A-selective endothelin receptor antagonist ambrisentan on digital ulcers in patients with systemic sclerosis: results of a prospective pilot study. Rademake[r] ...
10
Safety, efficacy, and clinical utility of macitentan in the treatment of pulmonary arterial hypertension
... is endothelin-1, which is a potent and long-lasting ...second-generation endothelin receptor antagonist that acts selectively as a pulmonary vaso- dilator without the significant side effects ...
8
Ambrisentan for the treatment of pulmonary arterial hypertension
... an endothelin receptor antagonist (ERA) that was recently approved for treatment of pulmonary arterial hypertension ...(PAH). Endothelin (ET) is a potent vasocon- strictor with mitogenic, ...
16
Selexipag in the treatment of pulmonary arterial hypertension: design, development, and therapy
... an endothelin receptor antagonist, a phosphodiesterase-5 inhibitor, or both, and to have a pulmonary vascular resistance (PVR) 5 Wood units at study ...
8
Prostanoid therapies in the management of pulmonary arterial hypertension
... Oral treprostinil for the treatment of pulmonary arterial hypertension in patients receiving background endothelin receptor antagonist and phosphodiesterase type 5 inhib[r] ...
13
Ginsenoside Re protects methamphetamine-induced dopaminergic neurotoxicity in mice via upregulation of dynorphin-mediated κ-opioid receptor and downregulation of substance P-mediated neurokinin 1 receptor
... -opioid receptor antagonist, counteracted against protective effects of ...NK1 receptor antagonist L-733,060 or GRe selectively inhibited microgliosis induced by ...NK1 receptor is one ...
22
Eye and heart morphogenesis are dependent on melatonin signaling in chick embryos
... receptor antagonist. This is because both the potency of the melatonin receptor antagonists and the G- protein levels were dependent on tissue ...melatonin receptor seemed to depend on the ...
10
Clinical use of extended-release oral treprostinil in the treatment of pulmonary arterial hypertension
... Treprostinil is currently the only FDA-approved oral pros- tacyclin for the treatment of PAH. While current evidence suggests that the drug is efficacious at improving exercise tolerance in treatment-naïve PAH patients, ...
7